English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Xalkori (crizotinib) – Conditions or restrictions regarding supply and use - L01XE16

Updated on site: 10-Oct-2017

Medication nameXalkori
ATC CodeL01XE16
Substancecrizotinib
ManufacturerPfizer Ltd

A.MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturer(s) responsible for batch release

Pfizer Manufacturing Deutschland GmbH

Mooswaldallee 1

79090 Freiburg

Germany

B.CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

Periodic Safety Update Reports

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

Risk Management Plan (RMP)

The MAH shall perform the required pharmacovigilance activities and intervetions detailed in the agreedRMP presented in Module 1.8.2. of the Marketing Authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

At the request of the European Medicine Agency;

Whenever the risk management system is modified, especially as the result of new information being received that may lead to significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

Additional risk minimisation measure

The Marketing Authorisation Holder (MAH) shall agree the content and format of the educational material with the National Competent Authority. The final wording used on the educational material should be in line with the approved product information.

The MAH should ensure that, at launch and thereafter, all Healthcare Professionals who are expected to use and/or prescribe XALKORI are provided with an educational pack.

The educational pack should contain the following:

1.Summary of Product Characteristics and Package Leaflet.

2.Patient brochure including a Patient Alert Card (text as agreed by the CHMP).

Comments

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
  • Help
  • Get it on Google Play
  • About
  • Info on site by:

  • Presented by RXed.eu

  • 27558

    prescription drugs listed